<?xml version="1.0" encoding="UTF-8"?>
<p>Erectile dysfunction or ED has been signified as an inability of the male to achieve a penile erection, as part of the overall multifaceted process of male sexual function [
 <xref rid="B1" ref-type="bibr">1</xref>]. ED status can arise in adult men of all ages, as its prevalence and incidence are associated with aging. The prevalence of ED in young men has been estimated to be as high as 30%, in which diabetes mellitus (DM) either type 1 or type 2 has a well-established and strong association with ED [
 <xref rid="B2" ref-type="bibr">2</xref>, 
 <xref rid="B3" ref-type="bibr">3</xref>]. The pathophysiology of diabetes-induced erectile dysfunction (DIED) is multifactorial and several mechanisms of ED have been proposed in diabetic patients, including increased oxygen free radicals and impaired nitric oxide (NO) synthesis [
 <xref rid="B4" ref-type="bibr">4</xref>]. The chronic hyperglycemia can lead to endothelial dysfunction, which is manifested as the decreased bioavailability of NO, resulting in insufficient relaxation of vascular smooth muscle of the corpora cavernosal [
 <xref rid="B5" ref-type="bibr">5</xref>]. The current first-line therapy for diabetic ED is phosphodiesterase type 5 inhibitors (PDE5Is), such as sildenafil (Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®). However, PDE5-Is has been shown to have some adverse effects, i.e., headache, abnormal vision, dyspepsia, flushing, nasal congestion, and back pain, which may impact negatively on patient's lifestyle [
 <xref rid="B6" ref-type="bibr">6</xref>].
</p>
